Welcome to our dedicated page for Omnicell news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell stock.
Omnicell, Inc. (NASDAQ: OMCL) develops healthcare technology for autonomous medication management across pharmacy and nursing care settings. Its updates cover financial results, product bookings, recurring revenue, connected-device demand, and product launches such as Omnicell Titan XT and the OmniSphere platform.
Company news also includes healthcare conference presentations, customer engagement programs, clinical leadership roles, and innovation updates tied to automation, AI-enabled intelligence, software workflows, data analytics, and expert services for medication management in healthcare facilities.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Omnicell, a leader in medication management, has partnered with Long Island University to open the Center for Innovative Medication Management (CIMM) in Brooklyn, New York. This state-of-the-art facility aims to enhance pharmacy education through advanced technology and analytics. The initiative allows pharmacy students to gain hands-on experience with medication management technologies, including robotics and software aimed at optimizing medication inventory. This strategic collaboration will also train Omnicell's operational teams, reinforcing the company’s commitment to improving pharmaceutical care delivery. The inaugural classes of the CIMM are set to commence in Summer 2023, emphasizing the importance of technology in preparing future pharmacy leaders.
Omnicell, a provider of medication management solutions, will release its first quarter 2023 financial results on May 2, 2023, after market close.
The company will host a conference call at 4:30 p.m. ET that same day to discuss these results. Interested parties can participate via phone or access a link to the live and archived webcast on the company's Investor Relations page.
Since 1992, Omnicell has focused on transforming pharmacy care delivery, aiming to improve outcomes and reduce costs through advanced automation and analytics. Its services support healthcare facilities in managing medications efficiently, enhancing patient safety, and reducing hospital readmissions.
Omnicell reported its fiscal year 2022 results, revealing total GAAP revenues of $1.296 billion, a 14% increase from 2021. However, fourth-quarter GAAP revenues decreased by 4% year-over-year, reflecting ongoing macroeconomic challenges. The company ended the year with over 150 long-term contracts with major U.S. health systems and a backlog of $1.215 billion. Notably, the Chief Financial Officer will step down on July 1, 2023. For 2023, Omnicell projects bookings between $1.000 billion to $1.100 billion and total revenues between $1.150 billion to $1.190 billion.
Omnicell, Inc. (NASDAQ: OMCL) is set to release its financial results for the fourth quarter and full year 2022 on February 28, 2023, after market close. A conference call is scheduled for 4:30 p.m. ET on the same day to discuss these results. Interested parties can listen to the call by dialing (888) 440-4318 in the U.S. or (267) 764-0566 internationally. Omnicell, established in 1992, focuses on transforming pharmacy care delivery through automation and technology, ultimately aiming to improve outcomes and lower costs.
Summary not available.